There are safe and effective vaccines that can prevent hepatitis A and B (but not cause types C, D, or E). There is also a combination vaccine that guards against A and B. Who Should Get the Hepatitis A Vaccine? The CDC recommends that all children between ages 12 months and 23 month...
Hepatitis B vaccines of half the recommended therapeutic dose are highly immunogenic and cost saving,PharmacoEconomics & Outcomes News -doi:10.1007/BF03272878NoneSpringer International PublishingPharmacoeconomics & Outcomes News
aged 13 to 17 years who had received three or more doses of the Hepatitis B vaccine Reasons for hesitancy Percentage of U.S. families that refused vaccines due to a fear of vaccinations causing autism Percentage of U.S. adults that refused the flu vaccine because they did not trust ...
Hepatitis B Vaccines and HPV Vaccines Have Been Hailed as Major Public Health Achievements in Preventing Cancer—Could a Schistosomiasis Vaccine be the Third? DOI: 10.1371/journal.pntd.0003598 Michael H. Hsieh?,Julia M. L. Brotherton?,Afzal A. Siddiqui Full-Text Cite this paper Add to My Lib...
To characterize adverse events (AEs) after hepatitis A vaccines (Hep A) and hepatitis A and hepatitis B combination vaccine (Hep AB) in pregnant women reported to the Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system. We searched VAERS for AEs reports in...
A tuberculosis history, both intra- and extrapulmonary, was the most frequent AIDS-associated disease (10.5%, n = 25). In relation to compliance with the recommended vaccines for PLHIV, the least compliant was the pneumococcal vaccine (Table 2). Table 2 Clinical characteristics of patients ...
environmental pollution, smoking, and gut microbiome) on inflammation and immune function, with a focus on the potential role of lifestyle changes in the prevention—or amelioration once established—of infectious diseases such as COVID-19, as well as their influence on the efficacy of vaccines. ...
The approval, from 1986, of a series of recombinant hepatitis B vaccines was a landmark both in the growth of biotechnology and in the development of the vaccine innovation system. In this paper, we show how the early development of the hepatitis B vaccines was shaped by a political and ec...
The path to successful hepatitis C elimination in Spain Strong multidisciplinary support and political commitment have helped Spain become one of the countries most likely to eliminate hepatitis C. In this Comment, we set out six key elements of the Spanish elimination effort that can serve as a...
4.1).2 Specifically contributing to this spectacular growth were the varicella, hepatitis A, pneumococcal conjugate, shingles, rotavirus, meningococcal conjugate for A, C, Y, W, and human papillomavirus (HPV) vaccines, as well as myriad combination vaccines. Download: Download full-size image ...